Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | TYMP | P19971 | 1/20 | 0.32 |
| ▸ | CTRC | Q99895 | 1/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3181988 | 0.91 | CA9 (0.53) | CA9 | |
| Acesulfame SCHEMBL3551 | 0.69 | CA9 (1.00) | CA9 | |
| Acesulfame SCHEMBL38656077 | 0.67 | CA9 (0.96) | CA9 | |
| Acesulfame SCHEMBL3126570 | 0.67 | CA9 (0.96) | CA9 | |
| Acesulfame SCHEMBL38654964 | 0.67 | CA9 (0.96) | CA9 | |
| Acesulfame SCHEMBL328775 | 0.67 | CA9 (0.96) | CA9 | |
| Acesulfame SCHEMBL38655123 | 0.67 | CA9 (0.96) | CA9 | |
| SCHEMBL20464776 | 0.66 | CA9 (0.32) | CA9DAO | |
| SCHEMBL4276744 | 0.64 | CA9 (0.32) | CA9 | |
| SCHEMBL4281978 | 0.63 | ALDH1A1 (0.36) | CA9GPR84KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10251392-B2 | Antimicrobial devices and compositions | AVENT, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-10251392-B2 | Antimicrobial devices and compositions | AVENT, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20180226675-A1 | BATTERY, BATTERY PACK, ELECTRONIC DEVICE, ELECTRIC VEHICLE, ELECTRIC STORAGE DEVICE, AND ELECTRIC POWER SYSTEM | MURATA MANUFACTURING CO., LTD. (JP) | 2018-08-09 | — | — | US | disclosed |
| US-20180226675-A1 | BATTERY, BATTERY PACK, ELECTRONIC DEVICE, ELECTRIC VEHICLE, ELECTRIC STORAGE DEVICE, AND ELECTRIC POWER SYSTEM | MURATA MANUFACTURING CO., LTD. (JP) | 2018-08-09 | — | — | US | disclosed |
| EP-2859961-A2 | Methods and compositions for metal nanoparticle treated surfaces | Avent, Inc. (US) | 2015-04-15 | — | — | EP | disclosed |
| EP-1991365-B1 | METHODS FOR FORMING SILVER-NANOPARTICLE TREATED SURFACES | KIMBERLY CLARK CO (US) | 2014-12-24 | — | — | EP | disclosed |
| US-20130122321-A1 | Methods and Compositions for Metal Nanoparticle Treated Surfaces | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130122321-A1 | Methods and Compositions for Metal Nanoparticle Treated Surfaces | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130122321-A1 | Methods and Compositions for Metal Nanoparticle Treated Surfaces | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8361553-B2 | Methods and compositions for metal nanoparticle treated surfaces | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8361553-B2 | Methods and compositions for metal nanoparticle treated surfaces | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8361553-B2 | Methods and compositions for metal nanoparticle treated surfaces | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20090035342-A1 | Antimicrobial Devices and Compositions | AVANOS MEDICAL SALES, LLC | 2009-02-05 | — | — | US | disclosed |
| US-20090035342-A1 | Antimicrobial Devices and Compositions | AVANOS MEDICAL SALES, LLC | 2009-02-05 | — | — | US | disclosed |
| US-20090035342-A1 | Antimicrobial Devices and Compositions | AVANOS MEDICAL SALES, LLC | 2009-02-05 | — | — | US | disclosed |
| US-20070207335-A1 | Methods and compositions for metal nanoparticle treated surfaces | AVANOS MEDICAL SALES, LLC | 2007-09-06 | — | — | US | disclosed |
| US-20070207335-A1 | Methods and compositions for metal nanoparticle treated surfaces | AVANOS MEDICAL SALES, LLC | 2007-09-06 | — | — | US | disclosed |
| US-20070207335-A1 | Methods and compositions for metal nanoparticle treated surfaces | AVANOS MEDICAL SALES, LLC | 2007-09-06 | — | — | US | disclosed |
| WO-2007095058-A2 | METHODS AND COMPOSITIONS FOR METAL NANOPARTICLE TREATED SURFACES | ACRYMED, INC. (US) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10251392-B2 | Antimicrobial devices and compositions | AAAS, AOC1, COL14A1 | CA9 1224/4885DAO 23/4885FFAR3 1370/4885 |
| US-20090035342-A1 | Antimicrobial Devices and Compositions | AAAS, AOC1, COL14A1 | CA9 1224/4885DAO 23/4885FFAR3 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.